
Translational Research Panel

Advancing Discoveries from the Research Bench to the Clinic

Paolo Decuzzi and Maria Teresa Peracchia

Laboratory of Nanotechnology for Precision Medicine
Italian Institute of Technology – Genoa (IT)
&
School of Medicine – Oncology
Stanford University – Stanford (USA)

Global Head CMC Strategy & Execution
mRNA Center of Excellence

Sanofi

OUR
SPEAKERS

CRS

Italy Local Chapter

CRS ITALIA -

"SCIENCE AND ENTREPRENEURSHIP" WEBINAR SERIES

MARCH – MAY 2022

2022

CRS Italia - "Science and Entrepreneurship" Webinar Series

February 25th
5 - 7 p.m.

Prof. Maria José ALONSO
Prof. Tejal DESAI
Prof. Samir MITRAGOTRI

Univ. Santiago de Compostela
Univ. California San Francisco
Harvard University

March 18th
4 - 5.30 p.m.

Prof. Rahima BENHABBOUR
Prof. Avi SCHROEDER

Univ. North Carolina
Technion

March 25th
5 - 6.30 p.m.

Dr. Ruth SCHMID
Dr. Matteo BONFANTI

SINTEF AS
Italian Institute of Technology

April 1st
4 - 5.30 p.m.

Prof. Ronit SATCHI-FAINARO
Prof. Steven LITTLE

Tel Aviv University
Univ. Pittsburgh

April 22nd
5 - 6.30 p.m.

Dr. Paola OCCHETTA
Dr. Giovanni MANFREDI
Dr. Devis GALESSO

BiomimX
Novavido
Fidia Farmaceutici

May 19th
5 - 7 p.m.

Dr. Marisa PAPALUCA
Dr. Marianne ASHFORD
Dr. Cristianne RIJCKEN
Dr. Eran EILAT


Imperial College London
AstraZeneca
Cristal Therapeutics
NeoVac

New opportunities and old challenges in the clinical translation of nanotheranostics

Peter J. Gawne^{1,2,3,8}, Miguel Ferreira^{4,8}, Mari

Abstract


Nanoparticle-based systems imbued with therapeutic functions, known as nanotheranostics, have made remarkable progress in guiding focal responses to endogenous and exogenous targets in preclinical models.




ría José Alonso^{3,4}, Marianne Ashford⁵, main⁷, Maria Kavallaris^{8,9},^{2,13}, Maria Teresa Peracchia¹⁴,¹, Cristianne J. F. Rijcken¹⁶,¹, Avi Schroeder²⁰,¹, horn²¹, Kathryn A. Whitehead²²,¹ s^{25,26,27}

igm shift in healthcare. Yet
revent or delay the clinical translation

A translational framework to DELIVER nanomedicines to the clinic



microneedles



Three clinically approved products:
2 vaccines; 1 ocular



Chair(s)



Paolo Decuzzi, PhD

Senior Scientist and Professor
Italian Institute of Technology

Co-Chair(s)



Maria Teresa Peracchia, PhD

Global head CMC strategy & execution, mRNA CoE
Sanofi

Panelist(s)



Aroa Duro Castaño, PhD (she/her/hers)

R&D Director
Research and Development
Curapath
Paterna, Comunidad Valenciana, Spain



Benjamin Winkeljann, PhD (he/him/his)

Group Leader
Pharmacy
Ludwig-Maximilians-University Munich
Munich, Bayern, Germany



Nicholas Hunt, BSc, PhD

Senior Lecturer
The University of Sydney, Australia



Jeff Hrkach

Advisor & Consultant, Boston (MA)



Brian Schanen, PhD

Global Head of Biomarkers
mRNA Center of Excellence | Sanofi



Hamideh Parhiz

Assistant Professor
Perelman School of Medicine at the University of Pennsylvania